Presentation is loading. Please wait.

Presentation is loading. Please wait.

Development of stable STZ-induced diabetes requires coexisting diet-induced impaired glucose tolerance. Development of stable STZ-induced diabetes requires.

Published byДмитрий Вельтман Modified over 5 years ago

Similar presentations

Presentation on theme: "Development of stable STZ-induced diabetes requires coexisting diet-induced impaired glucose tolerance. Development of stable STZ-induced diabetes requires."— Presentation transcript:

1 Development of stable STZ-induced diabetes requires coexisting diet-induced impaired glucose tolerance. Development of stable STZ-induced diabetes requires coexisting diet-induced impaired glucose tolerance. (A) Diagrammatic representation of optimized STZ treatment to induce hyperglycemia in guinea pigs fed either normal or HFHC diet. STZ powder is dissolved in citrate buffer at 100 mg/ml, then incubated for 2 h to allow for α/β anomer equilibration. Twenty minutes before STZ treatment, guinea pigs are administered a 0.5 mg/kg dose of the α2 agonist yohimbine, by the intramuscular (IM) route. Guinea pigs are then given a single 200 mg/kg subcutaneous (SC) injection of anomer-equilibrated STZ. Diabetic hyperglycemia is determined by an oral glucose tolerance test (OGTT) at day 7, 14 and 21, based on a 2 h blood glucose ≥200 mg/dl. (B) Blood glucose concentrations were measured daily at random in nonfasted, STZ-treated guinea pigs fed a normal diet (n=5). Hyperglycemia, observable 24 h after STZ treatment, has a trend of steady decline over the course of 14 days. *P<0.05 compared with day 1 post-STZ, one-way ANOVA. (C) Glucose tolerance was evaluated in STZ-treated guinea pigs (n=5) fed a normal diet by standardized oral glucose challenge on day 7, 14 and 21 after STZ treatment, and compared with normal-diet controls (n=5). Fasting hyperglycemia and diabetic glucose intolerance is evident 7 days after STZ treatment, but glucose intolerance diminishes over time, returning to nondiabetic tolerance after 21 days. **P<0.01, ***P<0.001, compared with mean glucose of normal-diet controls at 0, 60 and 120 min, or day 21 challenge of STZ guinea pigs at 150 min, two-way ANOVA. (D) HFHC-fed guinea pigs were treated with STZ after 8 weeks of consuming HFHC diet. Response to an oral glucose challenge is documented over 7, 14 and 21 days after STZ treatment that was preceded by 8 weeks of HFHC feeding (n=5 or 10). STZ treatment results in stable fasting hyperglycemia and diabetic glucose intolerance persisting to 21 days after treatment when guinea pigs are challenged in the presence of HFHC diet-induced impaired glucose tolerance. *P<0.05, ***P<0.001, compared with mean glucose of normal-diet controls at that measurement time point, one-way ANOVA based on mean area under the curve. Brendan K. Podell et al. Dis. Model. Mech. 2017;10: © Published by The Company of Biologists Ltd

Download ppt "Development of stable STZ-induced diabetes requires coexisting diet-induced impaired glucose tolerance. Development of stable STZ-induced diabetes requires."

Similar presentations

Diagnosis of diabetes. Diabetic symptoms Diabetic symptoms + venous sample for : –Random venous ≥ 11.1 mmol/l (4.4-7.8) –Fasting glucose > 7(

Diagnosis of diabetes. Diabetic symptoms Diabetic symptoms + venous sample for : –Random venous ≥ 11.1 mmol/l ( ) –Fasting glucose > 7(
Materials and Methods Phase 1 Evaluated acute effects on fasting blood glucose and on post-oral glucose Groups 1 and 3 received distilled water Groups.

Materials and Methods Phase 1 Evaluated acute effects on fasting blood glucose and on post-oral glucose Groups 1 and 3 received distilled water Groups.
 SC Guidelines for Diabetes Care 2011. Screening for Diagnosis of Diabetes To test for diabetes or to assess risk of future diabetes, either A1C, Fasting.

 SC Guidelines for Diabetes Care Screening for Diagnosis of Diabetes To test for diabetes or to assess risk of future diabetes, either A1C, Fasting.
Identify the risk factors, diagnosis and prevalence of diabetes in the United States. Describe the function of the pancreas, the intestines and liver.

Identify the risk factors, diagnosis and prevalence of diabetes in the United States. Describe the function of the pancreas, the intestines and liver.
TURNING PEPTIDES INTO DRUGS Background Materials & Methods 1) Bataille et al., FEBS Letters, 146, 79-86, 1982. 2) Gros et al., Endocrinology, 133, 631-638,

TURNING PEPTIDES INTO DRUGS Background Materials & Methods 1) Bataille et al., FEBS Letters, 146, 79-86, ) Gros et al., Endocrinology, 133, ,
The New Dual Glucagon-GLP-1 Agonist ZP2929 Improves Glycemic Control and Reduces Body Weight in Murine Models of Obesity and Type 2 Diabetes Jens R. Daugaard,

The New Dual Glucagon-GLP-1 Agonist ZP2929 Improves Glycemic Control and Reduces Body Weight in Murine Models of Obesity and Type 2 Diabetes Jens R. Daugaard,
Table 1. Pharmacokinetic Parameters of ZP2929 (from ref 1 & 2)

Table 1. Pharmacokinetic Parameters of ZP2929 (from ref 1 & 2)
(Oral glucose tolerance test OGTT)

(Oral glucose tolerance test OGTT)
Systemic Administration of Multipotent Mesenchymal Stromal Cells Reverts Hyperglycemia and Prevents Nephropathy in Type 1 Diabetic Mice  Fernando E. Ezquer,

Systemic Administration of Multipotent Mesenchymal Stromal Cells Reverts Hyperglycemia and Prevents Nephropathy in Type 1 Diabetic Mice  Fernando E. Ezquer,
Endovenous Administration of Bone Marrow-Derived Multipotent Mesenchymal Stromal Cells Prevents Renal Failure in Diabetic Mice  Fernando Ezquer, Marcelo.

Endovenous Administration of Bone Marrow-Derived Multipotent Mesenchymal Stromal Cells Prevents Renal Failure in Diabetic Mice  Fernando Ezquer, Marcelo.
Volume 137, Issue 6, Pages (December 2009)

Volume 137, Issue 6, Pages (December 2009)
Fig. 3. Fc fusion GDF15 molecules improve metabolic parameters in obese mice and obese cynomolgus monkeys. Fc fusion GDF15 molecules improve metabolic.

Fig. 3. Fc fusion GDF15 molecules improve metabolic parameters in obese mice and obese cynomolgus monkeys. Fc fusion GDF15 molecules improve metabolic.
Isotopic enrichment values of the equilibration time course for (A) oxygen-18 (18O) and (B) deuterium (2H) of three green turtles (Chelonia mydas). Isotopic.

Isotopic enrichment values of the equilibration time course for (A) oxygen-18 (18O) and (B) deuterium (2H) of three green turtles (Chelonia mydas). Isotopic.
Fig. 2. Effects of SFN in mouse hepatocytes and in rat models of diet-induced glucose intolerance. Effects of SFN in mouse hepatocytes and in rat models.

Fig. 2. Effects of SFN in mouse hepatocytes and in rat models of diet-induced glucose intolerance. Effects of SFN in mouse hepatocytes and in rat models.
Change in random blood glucose level, body weight, and intraperitoneal glucose tolerance test (IPGTT) in streptozotocin (STZ)-induced diabetic mice. Change.

Change in random blood glucose level, body weight, and intraperitoneal glucose tolerance test (IPGTT) in streptozotocin (STZ)-induced diabetic mice. Change.
Volume 18, Issue 13, Pages (March 2017)

Volume 18, Issue 13, Pages (March 2017)
Improvement of insulin sensitivity by treatment of the annexin A1 receptor agonist in HFD mice. Improvement of insulin sensitivity by treatment of the.

Improvement of insulin sensitivity by treatment of the annexin A1 receptor agonist in HFD mice. Improvement of insulin sensitivity by treatment of the.
Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.
Morphological alterations in pancreatic islets demonstrate a compensatory response to HFHC diet and STZ-induced β-cell loss. Morphological alterations.

Morphological alterations in pancreatic islets demonstrate a compensatory response to HFHC diet and STZ-induced β-cell loss. Morphological alterations.
Treatment with AAV8‐hAAT‐FGF21 improves insulin sensitivity and glucose tolerance Treatment with AAV8‐hAAT‐FGF21 improves insulin sensitivity and glucose.

Treatment with AAV8‐hAAT‐FGF21 improves insulin sensitivity and glucose tolerance Treatment with AAV8‐hAAT‐FGF21 improves insulin sensitivity and glucose.

Similar presentations

Ads by Google